|
Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder (青黄散) |
|
View Full Text View/Add Comment Download reader |
|
KeyWord: |
Author Name | Affiliation | E-mail | Shu Xu | Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China | | Rou Ma | Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China | xyxysys@yahoo.com.cn | Xiao-mei Hu | Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China | | Yong-gang Xu | Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China | | Xiao-hong Yang | Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China | | Hong-zhi Wang | Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China | | Shu-zhen Sun | Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China | | Feng Liu | Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China | |
|
Hits: 1161 |
Download times: 534 |
Abstract: |
Objective To observe the clinical effectiveness of Qinghuang Powder (青黄散, QHP) combined with Bupi Yishen Decoction (补脾益肾汤, BPYS) in treating myelodysplastic syndrome (MDS), and its relationship with France, America, and Britain (FAB) type, international prognosis scaling system (IPSS) risk, and chromosome karyotype. |
Close |
|
|
|